Serum antibody responses after intradermal vaccination against influenza
- PMID: 15525713
- DOI: 10.1056/NEJMoa043555
Serum antibody responses after intradermal vaccination against influenza
Abstract
Background: If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine.
Methods: In an open-label study, we randomly assigned 119 subjects to receive an intradermal injection of trivalent inactivated influenza vaccine, containing 6 mug of hemagglutinin for each antigen (40 percent of the usual dose), and 119 to receive an intramuscular injection of the standard dose of 15 mug of hemagglutinin for each antigen. The two groups were subdivided according to age (18 to 60 years and older than 60 years).
Results: Among subjects who were 18 to 60 years of age, serum antibody responses were vigorous and did not differ significantly between the intradermal and intramuscular groups, and all subjects had hemagglutination-inhibition (HAI) titers of at least 1:40. Although the subjects who were older than 60 years of age also had a vigorous antibody response, there was a trend toward a better response in the intramuscular route, but this finding was significant only for antigen to the H3N2 strain. Nevertheless, 100 percent of older subjects in the intramuscular group and 93 percent of such subjects in the intradermal group had an HAI antibody titer to the H3N2 strain of more than 1:40, and 100 percent in each group had a titer of this level for both the H1N1 and B strains. Local pain was significantly more common in the intramuscular group than in the intradermal group among subjects who were 18 to 60 years of age but not among subjects who were over 60 years old. Signs of local inflammation were significantly more common among subjects in the intradermal group than among those in the intramuscular group, in both age groups.
Conclusions: As compared with an intramuscular injection of full-dose influenza vaccine, an intradermal injection of a reduced dose resulted in similarly vigorous antibody responses among persons 18 to 60 years of age but not among those over the age of 60 years.
Copyright 2004 Massachusetts Medical Society.
Comment in
-
Intradermal influenza vaccination--can less be more?N Engl J Med. 2004 Nov 25;351(22):2330-2. doi: 10.1056/NEJMe048314. Epub 2004 Nov 3. N Engl J Med. 2004. PMID: 15525715 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. doi: 10.1056/NEJM200503103521019. N Engl J Med. 2005. PMID: 15758019 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. N Engl J Med. 2005. PMID: 15761999 No abstract available.
-
Intradermal vaccination against influenza.N Engl J Med. 2005 Mar 10;352(10):1044-6; author reply 1044-6. N Engl J Med. 2005. PMID: 15762000 No abstract available.
-
Intradermal injection of reduced-dose influenza vaccine was highly immunogenic in persons </= 60 years of age but less so in persons > 60 years.ACP J Club. 2005 May-Jun;142(3):68-9. ACP J Club. 2005. PMID: 15862067 No abstract available.
Similar articles
-
Dose sparing with intradermal injection of influenza vaccine.N Engl J Med. 2004 Nov 25;351(22):2295-301. doi: 10.1056/NEJMoa043540. Epub 2004 Nov 3. N Engl J Med. 2004. PMID: 15525714 Clinical Trial.
-
Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. Pediatrics. 2006. PMID: 16950949 Clinical Trial.
-
Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?Pediatrics. 2006 Sep;118(3):e570-8. doi: 10.1542/peds.2006-0198. Pediatrics. 2006. PMID: 16950948 Clinical Trial.
-
Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.Expert Rev Vaccines. 2010 Oct;9(10):1127-33. doi: 10.1586/erv.10.117. Expert Rev Vaccines. 2010. PMID: 20923264 Review.
-
Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis.JAMA Netw Open. 2021 Feb 1;4(2):e2035693. doi: 10.1001/jamanetworkopen.2020.35693. JAMA Netw Open. 2021. PMID: 33560425 Free PMC article.
Cited by
-
Microneedles for drug and vaccine delivery.Adv Drug Deliv Rev. 2012 Nov;64(14):1547-68. doi: 10.1016/j.addr.2012.04.005. Epub 2012 May 1. Adv Drug Deliv Rev. 2012. PMID: 22575858 Free PMC article. Review.
-
Dendritic cells in antifungal immunity and vaccine design.Cell Host Microbe. 2012 May 17;11(5):436-46. doi: 10.1016/j.chom.2012.04.005. Cell Host Microbe. 2012. PMID: 22607797 Free PMC article. Review.
-
Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection.Mol Ther. 2023 Feb 1;31(2):374-386. doi: 10.1016/j.ymthe.2022.10.011. Epub 2022 Oct 27. Mol Ther. 2023. PMID: 36303436 Free PMC article.
-
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
-
Immunization of Broiler Chickens With a Killed Chitosan Nanoparticle Salmonella Vaccine Decreases Salmonella Enterica Serovar Enteritidis Load.Front Physiol. 2022 Jul 18;13:920777. doi: 10.3389/fphys.2022.920777. eCollection 2022. Front Physiol. 2022. PMID: 35923229 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials